芪芍胶囊联合厄贝沙坦治疗糖尿病肾病

发布时间：2018-05-18 19:45

  本文选题：芪芍胶囊 + 糖尿病肾病　； 参考：《中国实验方剂学杂志》2016年03期

【摘要】：目的:探讨芪芍胶囊联合厄贝沙坦治疗糖尿病肾病(DKD)患者的疗效。方法:选取2014年1月至2015年4月期间河北省中医院收治的84例DKD患者为研究对象,并随机分为观察组和对照组,两组各42例。对照组给予厄贝沙坦治疗,150 mg qd,观察组在对照组治疗的基础上加用芪芍胶囊,5粒tid。比较两组治疗前后的糖代谢指标和肾功能指标,并比较两组患者的疗效。结果:治疗后观察组的空腹血糖(FPG),糖化血红蛋白(Hb A1c)均显著低于对照组(P0.05),治疗后观察组的血肌酐(SCr),尿蛋白排泄率(UAER),24 h尿蛋白(24 h UP),尿微量白蛋白(m ALB),尿微量白蛋白与肌酐比(m ALB/UCr),血尿素氮(BUN)分别为(135.7±18.9)μmol·L-1,(155.3±28.1)mg·(24 h)-1,(1.53±0.44)g,(39.7±12.9)μg·L-1,(15.5±3.9)mg·g-1,(6.59±0.87)mmol·L-1,均显著低于对照组的(163.6±18.0)μmol·L-1,(170.6±32.3)mg·(24 h)-1,(1.79±0.52)g,(47.4±14.4)μg·L-1,(17.7±3.8)mg·g-1,(7.06±0.93)mmol·L-1(P0.05)。观察组的临床疗效明显优于对照组(P0.05)。结论:与单用厄贝沙坦相比,芪芍胶囊联合厄贝沙坦治疗能更加显著地改善DKD患者的肾功能,延缓其进展,疗效显著,充分显示了中西医治疗的独特优势,值得临床推广应用。
[Abstract]:Objective: to investigate the curative effect of Qishao capsule combined with irbesartan on diabetic nephropathy (DKD) patients. Methods: from January 2014 to April 2015, 84 patients with DKD were randomly divided into observation group and control group, 42 cases in each group. The control group was treated with irbesartan 150 mg QD, and the observation group was treated with 5 capsules of Qishao capsule on the basis of the treatment in the control group. The indexes of glucose metabolism and renal function before and after treatment were compared between the two groups. Results: the fasting blood glucose level of observation group was significantly lower than that of control group (P 0.05). After treatment, the levels of serum creatinine, urinary protein excretion rate and urinary protein excretion rate in observation group were significantly lower than those in control group (P < 0.05). The urinary albumin excretion rate and urinary albumin excretion rate were 24 h, 24 h, and 24 h, respectively, respectively. 鐧戒笌鑲岄厫姣，

本文编号：1906964